FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310525084> ?p ?o ?g. }

• W4310525084 endingPage "3102" @default.
• W4310525084 startingPage "3102" @default.
• W4310525084 abstract "Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study, we investigated the synergistic and potentially enhanced efficacy of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in a mouse model. Baseline [68Ga]Ga-DOTA-TATE PET scans were obtained five days after athymic CD1 mice were inoculated with AR42J tumor cells, before separating the animals into four groups. Group 1 received a placebo, group 2 everolimus, group 3 a placebo and PRRT, and group 4 everolimus and PRRT. The treatment response was monitored by manually measuring the tumor volumes (manual tumor volume, MTV) and conducting sequential [68Ga]Ga-DOTA-TATE PET scans at one, two, and four weeks after treatment induction. The biological tumor volume (BTV) was derived from PET scans using threshold-based volume of interest (VOI) measurements. Tracer uptake was measured semi-quantitatively as a tumor to background ratio (TBR). Mice were euthanized due to excessive tumor growth according to the ethics protocol; blood samples were drawn for the preparation of full blood counts and kidneys were obtained for histological analysis. For the histological assessment, a standardized score (renal damage score, RDS) was used. Full blood counts showed significantly increased numbers of neutrophils and lymphocytes in the groups receiving PRRT. All other parameters did not differ relevantly. In the histological analysis, groups receiving PRRT had a significantly higher RDS, whereas everolimus only tended to cause an increase in the RDS. Mice in groups 1 and 2 had to be euthanized due to excessive tumor growth two weeks after the start of the therapy, whereas follow-up in groups 3 and 4 comprised four weeks. PRRT significantly inhibited tumor growth; the administration of everolimus did not induce an additional effect. A good correlation existed between MTV and BTV. PRRT significantly reduced the TBR. [68Ga]Ga-DOTA-TATE PET is suitable for monitoring tumor growth in the applied model. The high efficacy of [177Lu]Lu-DOTA-TATE is not enhanced by the combination with everolimus." @default.
• W4310525084 created "2022-12-11" @default.
• W4310525084 creator A5000041206 @default.
• W4310525084 creator A5001164379 @default.
• W4310525084 creator A5002308372 @default.
• W4310525084 creator A5004272744 @default.
• W4310525084 creator A5004699895 @default.
• W4310525084 creator A5037412930 @default.
• W4310525084 creator A5048708393 @default.
• W4310525084 creator A5053048077 @default.
• W4310525084 creator A5057027148 @default.
• W4310525084 creator A5066632751 @default.
• W4310525084 creator A5073865953 @default.
• W4310525084 date "2022-12-01" @default.
• W4310525084 modified "2023-10-01" @default.
• W4310525084 title "Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors" @default.
• W4310525084 cites W1453000988 @default.
• W4310525084 cites W2017550948 @default.
• W4310525084 cites W2041024134 @default.
• W4310525084 cites W2045946446 @default.
• W4310525084 cites W2047558841 @default.
• W4310525084 cites W2053911720 @default.
• W4310525084 cites W2054703028 @default.
• W4310525084 cites W2055050697 @default.
• W4310525084 cites W2061408583 @default.
• W4310525084 cites W2073692301 @default.
• W4310525084 cites W2075075102 @default.
• W4310525084 cites W2115686439 @default.
• W4310525084 cites W2136907822 @default.
• W4310525084 cites W2143842256 @default.
• W4310525084 cites W2160363302 @default.
• W4310525084 cites W2209368665 @default.
• W4310525084 cites W2282633338 @default.
• W4310525084 cites W2573369749 @default.
• W4310525084 cites W2608160487 @default.
• W4310525084 cites W2765638631 @default.
• W4310525084 cites W2884335981 @default.
• W4310525084 cites W3018299836 @default.
• W4310525084 cites W3036666213 @default.
• W4310525084 cites W3084275480 @default.
• W4310525084 cites W3086431826 @default.
• W4310525084 cites W3094456955 @default.
• W4310525084 cites W3192494717 @default.
• W4310525084 doi "https://doi.org/10.3390/biomedicines10123102" @default.
• W4310525084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36551858" @default.
• W4310525084 hasPublicationYear "2022" @default.
• W4310525084 type Work @default.
• W4310525084 citedByCount "0" @default.
• W4310525084 crossrefType "journal-article" @default.
• W4310525084 hasAuthorship W4310525084A5000041206 @default.
• W4310525084 hasAuthorship W4310525084A5001164379 @default.
• W4310525084 hasAuthorship W4310525084A5002308372 @default.
• W4310525084 hasAuthorship W4310525084A5004272744 @default.
• W4310525084 hasAuthorship W4310525084A5004699895 @default.
• W4310525084 hasAuthorship W4310525084A5037412930 @default.
• W4310525084 hasAuthorship W4310525084A5048708393 @default.
• W4310525084 hasAuthorship W4310525084A5053048077 @default.
• W4310525084 hasAuthorship W4310525084A5057027148 @default.
• W4310525084 hasAuthorship W4310525084A5066632751 @default.
• W4310525084 hasAuthorship W4310525084A5073865953 @default.
• W4310525084 hasBestOaLocation W43105250841 @default.
• W4310525084 hasConcept C126322002 @default.
• W4310525084 hasConcept C126894567 @default.
• W4310525084 hasConcept C142724271 @default.
• W4310525084 hasConcept C183713625 @default.
• W4310525084 hasConcept C185592680 @default.
• W4310525084 hasConcept C190283241 @default.
• W4310525084 hasConcept C204787440 @default.
• W4310525084 hasConcept C27081682 @default.
• W4310525084 hasConcept C2776694085 @default.
• W4310525084 hasConcept C2778822529 @default.
• W4310525084 hasConcept C2779066768 @default.
• W4310525084 hasConcept C2779699572 @default.
• W4310525084 hasConcept C2779984678 @default.
• W4310525084 hasConcept C2989005 @default.
• W4310525084 hasConcept C2993559085 @default.
• W4310525084 hasConcept C55493867 @default.
• W4310525084 hasConcept C71924100 @default.
• W4310525084 hasConcept C86554907 @default.
• W4310525084 hasConceptScore W4310525084C126322002 @default.
• W4310525084 hasConceptScore W4310525084C126894567 @default.
• W4310525084 hasConceptScore W4310525084C142724271 @default.
• W4310525084 hasConceptScore W4310525084C183713625 @default.
• W4310525084 hasConceptScore W4310525084C185592680 @default.
• W4310525084 hasConceptScore W4310525084C190283241 @default.
• W4310525084 hasConceptScore W4310525084C204787440 @default.
• W4310525084 hasConceptScore W4310525084C27081682 @default.
• W4310525084 hasConceptScore W4310525084C2776694085 @default.
• W4310525084 hasConceptScore W4310525084C2778822529 @default.
• W4310525084 hasConceptScore W4310525084C2779066768 @default.
• W4310525084 hasConceptScore W4310525084C2779699572 @default.
• W4310525084 hasConceptScore W4310525084C2779984678 @default.
• W4310525084 hasConceptScore W4310525084C2989005 @default.
• W4310525084 hasConceptScore W4310525084C2993559085 @default.
• W4310525084 hasConceptScore W4310525084C55493867 @default.
• W4310525084 hasConceptScore W4310525084C71924100 @default.
• W4310525084 hasConceptScore W4310525084C86554907 @default.
• W4310525084 hasIssue "12" @default.

• next